Navigation Links
Schering-Plough Reports Financial Results for 2009 Second Quarter
Date:7/21/2009

financial statements presented in accordance with accounting principles generally accepted in the United States of America (U.S. GAAP), Schering-Plough is providing the supplemental financial information below and on the following pages to reflect "As Reconciled" amounts related to Net income available to common shareholders and Diluted earnings per common share. "As Reconciled" amounts exclude the effects of purchase accounting adjustments, special and acquisition-related items and other specified items. "As Reconciled" amounts related to Net income available to common shareholders and Diluted earnings per common share are non-U.S. GAAP measures used by management in evaluating the performance of Schering-Plough's overall business. The effects of purchase accounting adjustments, special and acquisition-related items and other specified items have been excluded from Net income available to common shareholders and Diluted earnings per common share as management of Schering-Plough does not consider these charges to be indicative of continuing operating results. Schering-Plough believes that these "As Reconciled" performance measures contribute to a more complete understanding by investors of the overall results of the company and enhances investor understanding of items that impact the comparability of results between fiscal periods. Net income available to common shareholders and Diluted earnings per common share, as reported, are required to be presented under U.S. GAAP. Three months ended June 30, 2009 (unaudited) ----------- Special, Purchase Merger and Accounting Acquisition- Other As
'/>"/>
SOURCE Schering-Plough Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27

Related biology technology :

1. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
2. Schering-Plough Announces Pricing of Senior Notes Offering
3. Schering-Plough to Webcast Presentation at Merrill Lynch Global Pharmaceutical, Biotech & Medtech Conference
4. Schering-Plough Receives Approval from European Commission for Planned Acquisition of Organon BioSciences N.V.
5. Schering-Plough Completes Acquisition of Organon BioSciences
6. Schering-Plough Wins Three of Scrips Top Pharma Industry Awards
7. Schering-Plough Schedules Conference Call and Webcast for 2007 Fourth Quarter, Full-Year Financial Result
8. Schering-Plough to Webcast Presentation at Morgan Stanley Pharmaceutical CEOs Unplugged Conference
9. Schering-Plough Announces New Drug Application for Sugammadex Assigned Priority Review Status by U.S. FDA
10. Schering-Plough Announces Sugammadex New Drug Application Filed in Japan
11. FDA Grants Priority Review for Schering-Ploughs Peginterferon Alfa-2b for the Adjuvant Treatment of Patients With Stage III Melanoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... July 29, 2015 /PRNewswire/ - RepliCel Life Sciences Inc. ... medicine company, is pleased to announce that the final ... have been locked.  Prototypes for industrial and regulatory ... an application for CE mark clearance to market ... in 2016. (Photo: http://photos.prnewswire.com/prnh/20150729/248373 )  ...
(Date:7/29/2015)... ... ... Costello served as Lead Levee Design Engineering Manager for a feasibility study of ... future storm surge flooding, such as occurred in Hurricane Ike in 2008. , ... protection, Costello also balanced socio-economic and environmental needs and concerns. The team ...
(Date:7/28/2015)... ... July 29, 2015 , ... Strong Animals™ announced today that research conducted by ... presented at the ADSA-ASAS Joint Annual Meeting held July 12-16 in Orlando, FL showed ... increased milk fat content. Also, feed containing Stay Strong™ for Dairy Cows took longer ...
(Date:7/28/2015)... , ... July 28, 2015 , ... ... than EUR 1.022 billion in 2013; while production volume reached close to 1.84 ... producing country with a share of 75.5% of the region’s total aluminium hydroxide ...
Breaking Biology Technology:RepliCel Life Sciences Unveils Innovative Dermal Injector Prototype 2RepliCel Life Sciences Unveils Innovative Dermal Injector Prototype 3RepliCel Life Sciences Unveils Innovative Dermal Injector Prototype 4RepliCel Life Sciences Unveils Innovative Dermal Injector Prototype 5Preventing Storm Surge Flooding in Houston 2Strong Animals™ Announces South Dakota State University Research Demonstrates Stay Strong™ for Dairy Cows Improves Performance and Feed Stability 2EU27 Aluminium Hydroxide Market Analysed and Forecast by BAC Reports in New Research Study Available at MarketPublishers.com 2EU27 Aluminium Hydroxide Market Analysed and Forecast by BAC Reports in New Research Study Available at MarketPublishers.com 3
... Published in the ... Academy of Sciences, MOUNTAIN VIEW, Calif., Sept. 26 ... developing,and commercializing therapeutics that target the chemokine system, today,announced ... experiments to,elucidate CXCR7,s essential role in the progression and ...
... Dana C. Hilt Named SVP, Clinical Development & ... EnVivo Pharmaceuticals,Inc., a privately held biopharmaceutical company ... of Dr. Dana C.,Hilt as Senior Vice President ... coordinating all pre-clinical and clinical development,activities of EnVivo,s ...
... Materials for Food and Other Packaging Uses, ... (NYSE: DD ) and Plantic Technologies Limited, ... plans to,collaborate in the development and sale of ... include the collaborative development of new, renewably sourced,resins ...
Cached Biology Technology:ChemoCentryx Demonstrates Recently Discovered Chemokine Receptor CXCR7 is Essential in Tumor Growth 2ChemoCentryx Demonstrates Recently Discovered Chemokine Receptor CXCR7 is Essential in Tumor Growth 3ChemoCentryx Demonstrates Recently Discovered Chemokine Receptor CXCR7 is Essential in Tumor Growth 4ChemoCentryx Demonstrates Recently Discovered Chemokine Receptor CXCR7 is Essential in Tumor Growth 5EnVivo Pharmaceuticals Announces Executive Appointment 2DuPont and Plantic Technologies Announce Starch-Based Bio Materials Collaboration 2DuPont and Plantic Technologies Announce Starch-Based Bio Materials Collaboration 3
(Date:7/7/2015)... VIEW, Calif. , July 7, 2015 /PRNewswire/ ... biometrics market, Frost & Sullivan recognizes Credence ID, ... Sullivan Entrepreneurial Company of the Year Award. ... suite to aid in its mission of offering ... under-recognized populations globally. As Credence ID was formed ...
(Date:7/2/2015)... 25, 2015 Research and ... "Next Generation Biometrics Market by Application, Technology, Function ... to their offering. The next generation biometrics ... at a CAGR of 17.9% between 2015 and 2020 ... for the market. Safran SA ( ...
(Date:6/30/2015)... , June 30, 2015 Genisphere ... company as CEO to help further develop Genisphere,s therapeutics ... of partnering experience, having spent much of the last ... Therakine, Amgen, Baxter Bioscience, and Johnson & Johnson. Tom ... on Technology and Biotech Corporate Finance. He graduated from ...
Breaking Biology News(10 mins):Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 2Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 4Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 5Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 2Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 3Genisphere Appoints New CEO, Thomas Bliss 2Genisphere Appoints New CEO, Thomas Bliss 3
... perennially covered in ice. It is exposed to severe ... and, during the winter, 24-hour darkness. But, for the ... To study them, Dr. Rachel Morgan-Kiss from the University ... to sample the ice-covered lake. The article describing her ...
... 2012 Researchers at the Hebrew University of Jerusalem and ... that produce very abundant biochemical products in the cell and ... flexible subset that might have abnormal function in a disease. ... found among various organisms and cell types, including stem cells ...
... Africa could benefit from access to treatment for an endemic ... of infection. Researchers tested hundreds of children aged between ... fever also known as bilharzia or schistosomiasis is ... they are perceived to be at low risk of exposure ...
Cached Biology News:Research on carbon-consuming life-forms in Antarctica published in JoVE 2Treatment to benefit African infants at risk of endemic fever 2
... The Rapid-Screen cDNA Library Panels were ... just three sets of PCRs to identify ... analysis is performed in a 96-well "Master ... from 5,000 clones. Having identified the positive ...
... The ProteinChip beta-amyloid Multipeptide Kit, ... Systems, makes detecting a variety of ... than ever before. - Clinical neuroscience ... after drug treatment - Correlate beta-amyloid ...
Formula variant: With the macro- and micronutrients as described by Lloyd and McCown (1981). Preparation Quantity Equivalency: Formulated to contain 2.3 grams of powder per liter of medium. Physical ...
... Biosystems and MDS Sciex present the ... high performance hybrid triple quadrupole/linear ion ... discovery, drug development or proteomics researcher. ... from the leaders in mass spectrometry ...
Biology Products: